Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CapForce Inc.OPGN · Entity 9776 | Director | June 13, 2018 | June 15, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CapForce Inc.
Report date June 13, 2018 · Filed June 15, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.30 · Expires 2028-06-13 | Direct | 2,500 |
Reported balance
After 2018-06-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-13 · Grant · Acquired 2,500 · Balance 2,500 F1: The option vests 25% on each of July 1, 2018, October 1, 2018, January 1, 2019 and April 1, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests 25% on each of July 1, 2018, October 1, 2018, January 1, 2019 and April 1, 2019.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Bioverativ Inc.
Report date March 08, 2018 · Filed March 08, 2018
Section 16 reporting ended · disclosed 2018-03-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-03-08 transaction · row 1
1 source rowRow 1 · 2018-03-08 · Disposition to issuer · Disposed 838.9492 · Balance 0 F1: Includes an aggregate of 757.9492 shares acquired under the Company's Employee Stock Purchase Plan on September 29, 2017, December 29, 2017 and March 6, 2018. F2: Pursuant to the Agreement and Plan of Merger, dated as of January 21, 2018 (the "Merger Agreement"), between the Company, Sanofi, a French soci?t? anonyme (the "Parent"), and Blink Acquisition Corp. ("Merger Sub"), on March 8, 2018, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $105.00 in cash. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-03-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-03-08 · Disposition to issuer · Disposed 11,271 · Balance 0 F3: Each restricted stock unit ("RSU") represents a contingent right to receive one Share of the issuer's common stock. F4: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-03-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-03-08 · Disposition to issuer · Disposed 40,909 · Balance 0 F3: Each restricted stock unit ("RSU") represents a contingent right to receive one Share of the issuer's common stock. F4: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. |
| Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $56.34 | Direct | 0 |
Reported balance
After 2018-03-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-03-08 · Disposition to issuer · Disposed 34,556 · Balance 0 F5: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. |
| Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $56.34 | Direct | 0 |
Reported balance
After 2018-03-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-03-08 · Disposition to issuer · Disposed 33,759 · Balance 0 F5: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes an aggregate of 757.9492 shares acquired under the Company's Employee Stock Purchase Plan on September 29, 2017, December 29, 2017 and March 6, 2018.
F2: Pursuant to the Agreement and Plan of Merger, dated as of January 21, 2018 (the "Merger Agreement"), between the Company, Sanofi, a French soci?t? anonyme (the "Parent"), and Blink Acquisition Corp. ("Merger Sub"), on March 8, 2018, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $105.00 in cash.
F3: Each restricted stock unit ("RSU") represents a contingent right to receive one Share of the issuer's common stock.
F4: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes.
F5: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 13, 2018 Filed Jun 15, 2018 17:04 UTC | CapForce Inc. OPGN · Entity 9776 | GrantStock Option · Derivative | 2,500 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0001140361-18-028814 · doc1.xml · derivative · entry 1 Harris Timothy J.R. · CIK 0001419958 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2028-06-13 F1 · derivative.exercise_date: The option vests 25% on each of July 1, 2018, October 1, 2018, January 1, 2019 and April 1, 2019. Read SEC document |
| March 08, 2018 Filed Mar 8, 2018 12:36 UTC | Bioverativ Inc. BIVV · Entity 168487 | Disposition to issuerNon-Qualified Stock Option · Derivative | 33,759 | Not disclosed Strike: $56.34 | Not disclosed |
DisclosureSEC source: 0001127602-18-010666 · form4.xml · derivative · entry 5 Harris Timothy J.R. · CIK 0001419958 · EVP, R & D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,759 shares Expires not disclosed F5 · shares: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. F5 · price: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. F5 · derivative.expiration_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. Read SEC document |
| March 08, 2018 Filed Mar 8, 2018 12:36 UTC | Bioverativ Inc. BIVV · Entity 168487 | Disposition to issuerNon-Qualified Stock Option · Derivative | 34,556 | Not disclosed Strike: $56.34 | Not disclosed |
DisclosureSEC source: 0001127602-18-010666 · form4.xml · derivative · entry 4 Harris Timothy J.R. · CIK 0001419958 · EVP, R & D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,556 shares Expires not disclosed F5 · shares: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. F5 · price: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. F5 · derivative.expiration_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. Read SEC document |
| March 08, 2018 Filed Mar 8, 2018 12:36 UTC | Bioverativ Inc. BIVV · Entity 168487 | Disposition to issuerRestricted Stock Units · Derivative | 40,909 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-010666 · form4.xml · derivative · entry 3 Harris Timothy J.R. · CIK 0001419958 · EVP, R & D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,909 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one Share of the issuer's common stock. F4 · shares: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. F4 · price: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. Read SEC document |
| March 08, 2018 Filed Mar 8, 2018 12:36 UTC | Bioverativ Inc. BIVV · Entity 168487 | Disposition to issuerRestricted Stock Units · Derivative | 11,271 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-010666 · form4.xml · derivative · entry 2 Harris Timothy J.R. · CIK 0001419958 · EVP, R & D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,271 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one Share of the issuer's common stock. F4 · shares: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. F4 · price: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. Read SEC document |
| March 08, 2018 Filed Mar 8, 2018 12:36 UTC | Bioverativ Inc. BIVV · Entity 168487 | Disposition to issuerCommon Stock | 838.9492 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-010666 · form4.xml · nonDerivative · entry 1 Harris Timothy J.R. · CIK 0001419958 · EVP, R & D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Includes an aggregate of 757.9492 shares acquired under the Company's Employee Stock Purchase Plan on September 29, 2017, December 29, 2017 and March 6, 2018. F2 · price: Pursuant to the Agreement and Plan of Merger, dated as of January 21, 2018 (the "Merger Agreement"), between the Company, Sanofi, a French soci?t? anonyme (the "Parent"), and Blink Acquisition Corp. ("Merger Sub"), on March 8, 2018, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $105.00 in cash. Read SEC document |
| January 31, 2018 Filed Feb 2, 2018 17:22 UTC | Bioverativ Inc. BIVV · Entity 168487 | GrantRestricted Stock Units · Derivative | 40,909 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-003824 · form4.xml · derivative · entry 1 Harris Timothy J.R. · CIK 0001419958 · EVP, R & D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,909 Underlying: Common Stock · 40,909 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning on January 31, 2019. F2 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning on January 31, 2019. Read SEC document |
| August 25, 2017 Filed Aug 29, 2017 17:44 UTC | CapForce Inc. OPGN · Entity 9776 | GrantCommon Stock | 39,292 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-033575 · doc1.xml · nonDerivative · entry 1 Harris Timothy J.R. · CIK 0001419958 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,408 F1 · security: Represents an award of restricted stock units vesting on October 1, 2017. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 16:35 UTC | CapForce Inc. OPGN · Entity 9776 | GrantStock Option · Derivative | 12,500 | $0.00 Strike: $0.66 | $0.00 |
DisclosureSEC source: 0001140361-17-024688 · doc1.xml · derivative · entry 1 Harris Timothy J.R. · CIK 0001419958 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2027-06-08 F1 · derivative.exercise_date: The option vests 25% on each of July 1, 2017, October 1, 2017, January 1, 2018 and April 1, 2018. Read SEC document |
| April 10, 2017 Filed Apr 11, 2017 16:14 UTC | Bioverativ Inc. BIVV · Entity 168487 | GrantRestricted Stock Units · Derivative | 11,271 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-014630 · form4.xml · derivative · entry 3 Harris Timothy J.R. · CIK 0001419958 · EVP, R & D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,271 Underlying: Common Stock · 11,271 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: The restricted stock units vest in two equal annual installments beginning on April 10, 2018. F4 · derivative.expiration_date: The restricted stock units vest in two equal annual installments beginning on April 10, 2018. Read SEC document |
| April 10, 2017 Filed Apr 11, 2017 16:14 UTC | Bioverativ Inc. BIVV · Entity 168487 | GrantNon-Qualified Stock Option · Derivative | 33,759 | $0.00 Strike: $56.34 | $0.00 |
DisclosureSEC source: 0001127602-17-014630 · form4.xml · derivative · entry 2 Harris Timothy J.R. · CIK 0001419958 · EVP, R & D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,759 Underlying: Common Stock · 33,759 shares Expires 2027-04-10 F2 · derivative.exercise_date: This option vests in two equal annual installments beginning on April 10, 2018. Read SEC document |
| April 10, 2017 Filed Apr 11, 2017 16:14 UTC | Bioverativ Inc. BIVV · Entity 168487 | GrantNon-Qualified Stock Option · Derivative | 34,556 | $0.00 Strike: $56.34 | $0.00 |
DisclosureSEC source: 0001127602-17-014630 · form4.xml · derivative · entry 1 Harris Timothy J.R. · CIK 0001419958 · EVP, R & D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,556 Underlying: Common Stock · 34,556 shares Expires 2027-04-10 F1 · derivative.exercise_date: This option vests in full on the second anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.